Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
September 1, 2025 Teva Pharmaceuticals achieved a landmark milestone when the US Food and Drug Administration (FDA) approved a first-of-its-kind launch of a generic glucagon-like peptide-1 (GLP-1)
It is the leading cause of irreversible blindness globally, with projections indicating it could affect over 100 million individuals by 2040 (74)
Members receive 2 complimentary ebooks: The Mayo Clinic Diet: Weight-Loss Medications Edition and Cook Smart, Eat Well
Currently, there is no evidence suggesting that GLP-1 medications reduce effectives of non-oral contraception
Created1/15/2026
Some of the important products it employs include Avastin to treat solid tumors, Herceptin to treat HER2-positive breast cancer, and Rituxan to treat hematologic tumors and autoimmune diseases
US$ 29.70
US$ 22.33
US$ 27.02
US$ 25.69
US$ 23.75
